Cytori Therapeutics (NASDAQ:CYTX) has been given a $2.00 price target by Maxim Group in a note issued to investors on Friday. The firm presently has a “buy” rating on the biotechnology company’s stock.

CYTX has been the topic of a number of other research reports. Zacks Investment Research downgraded shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Laidlaw reissued a “buy” rating and set a $1.65 price objective on shares of Cytori Therapeutics in a report on Thursday, February 22nd. Finally, ValuEngine raised shares of Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $1.80.

Shares of Cytori Therapeutics (NASDAQ CYTX) opened at $0.32 on Friday. The company has a market cap of $11.06, a PE ratio of -0.36 and a beta of 3.49. Cytori Therapeutics has a fifty-two week low of $0.22 and a fifty-two week high of $2.08.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The company had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $2.00 million. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. analysts anticipate that Cytori Therapeutics will post -0.68 earnings per share for the current fiscal year.

In other Cytori Therapeutics news, major shareholder Ag Postfinance sold 286,982 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $0.31, for a total value of $88,964.42. Following the sale, the insider now owns 5,118,627 shares of the company’s stock, valued at $1,586,774.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the company’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total transaction of $38,000.00. Following the completion of the sale, the insider now directly owns 5,496,655 shares in the company, valued at approximately $2,088,728.90. The disclosure for this sale can be found here. In the last three months, insiders have sold 695,767 shares of company stock worth $231,951. 1.90% of the stock is owned by insiders.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Vanguard Group Inc. raised its holdings in Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 612,304 shares of the biotechnology company’s stock after purchasing an additional 275,653 shares during the period. Vanguard Group Inc. owned 1.89% of Cytori Therapeutics worth $674,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.57% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Cytori Therapeutics (CYTX) PT Set at $2.00 by Maxim Group” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.